Abstract:Emerging and recurrent infectious diseases caused by coronaviruses remain a significant public health concern. Here, we present a targeted approach to elicit antibodies capable of neutralizing SARS-CoV-2 variants and other SARS-related coronaviruses. By introducing amino acid mutations at mutation-prone sites, we engineered glycosylation modifications to the Receptor Binding Domain (RBD) of SARS-CoV-2, thereby exposing more conserved, yet less accessible epitopes. We developed both messenger RNA (mRNA) and recombination subunit vaccines using these engineered-RBDs (M1, M2) and the wild-type RBD as immunogens. The engineered-RBD vaccines elicited robust neutralizing responses against various SARS-CoV-2 variants as well as SARS-CoV and WIV1-CoV, and conferred protection in mice challenged with the XBB.1.16 strain. Furthermore, We highlighted that glycan masking is a decisive factor in antibody binding changes and RBD-conserved antibody response. Additionally, the glycan-engineered RBD mRNA vaccines stimulated stronger cell-mediated immune responses. Our glycan modification strategy significantly enhances broad-spectrum neutralizing efficacy and cellular immunity, providing valuable insights for the development of vaccines against a wide range of SARS-related coronaviruses. Since late 2020, numerous SARS-CoV-2 variants have emerged across different regions, with the Omicron variant and its subvariants (e.g., BA.5, XBB, JN.1, etc.) posing significant challenges to ongoing efforts in controlling the pandemic. This highlights the urgent need for broadly protective vaccines that target both SARS-CoV-2 variants and other SARS-related coronaviruses that could cause future outbreaks. In this study, we developed a glycan modification strategy based on N-glycosylation by introducing amino acid mutations in the RBD. Using these engineered RBDs (M1, M2) and wild-type RBD as immunogens, we created thermostable mRNA vaccines and recombinant subunit vaccines. Our results demonstrate that these engineered-RBD vaccines elicit potent neutralizing responses against notonly various SARS-CoV-2 variants, but also other coronaviruses like SARS-CoV and WIV1-CoV, surpassing the immune response triggered by the wild-type RBD. Furthermore, glycan-engineered RBD mRNA vaccines stimulated stronger cell-mediated immune responses and provided effective protection against XBB strain challenge in mice. We identified key glycosylation modifications at residues K417, L452, R457, and Q493 that play a critical role in inducing broad-spectrum neutralizing antibodies. In particular, the glycosylation of residues R457 and Q493 was especially effective in enhancing this immune response. These findings offer valuable insights for the design of broad-spectrum vaccines against SARS-related coronaviruses.

Inducing Long Lasting B Cell and T Cell Immunity Against Multiple Variants of SARS-CoV-2 Through Mutant Bacteriophage Qβ-Receptor Binding Domain Conjugate

Intranasal administration of a recombinant RBD vaccine induces long-term immunity against Omicron-included SARS-CoV-2 variants

A Bivalent COVID-19 Vaccine Based on Alpha and Beta Variants Elicits Potent and Broad Immune Responses in Mice against SARS-CoV-2 Variants

Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccine

Design of a mutation-integrated trimeric RBD with broad protection against SARS-CoV-2

A protein vaccine of RBD integrated with immune evasion mutation shows broad protection against SARS-CoV-2

Inducing Enhanced Neutralizing Antibodies Against Broad SARS-CoV-2 Variants Through Glycan-Shielding Multiple Non-Neutralizing Epitopes of RBD

Recombinant SARS-CoV-2 RBD with a built in T helper epitope induces strong neutralization antibody response

Development of Glycan-masked SARS-CoV-2 RBD vaccines against SARS-related coronaviruses

Enhanced protective efficacy of a thermostable RBD-S2 vaccine formulation against SARS-CoV-2 and its variants

A Vaccine of SARS-CoV-2 S Protein RBD Induces Protective Immunity

Neutralization of SARS-CoV-2 BA.2.86 and JN.1 by CF501 Adjuvant-Enhanced Immune Responses Targeting the Conserved Epitopes in Ancestral RBD.

Vaccine-induced and hybrid immunity against SARS-CoV-2 variants of concern in two cohorts in Queensland, Australia (2021-2022).

Development of Broad-Spectrum Nanobodies for the Therapy and Diagnosis of SARS-CoV-2 and Its Multiple Variants

Finally neutralizing the threat? A novel SARS-CoV-2 vaccine platform that elicits enhanced neutralizing antibody responses

A Delta-Omicron Bivalent Subunit Vaccine Elicited Antibody Responses in Mice against Both Ancestral and Variant Strains of SARS-CoV-2

Adjuvant-Protein Conjugate Vaccine with Built-In TLR7 Agonist on S1 Induces Potent Immunity against SARS-CoV-2 and Variants of Concern

Broad protective RBD heterotrimer vaccines neutralize SARS-CoV-2 including Omicron sub-variants XBB/BQ.1.1/BF.7

Dosing interval regimen shapes potency and breadth of antibody repertoire after vaccination of SARS-CoV-2 RBD protein subunit vaccine

RBD-mRNA Vaccine Induces Broadly Neutralizing Antibodies Against Omicron and Multiple Other Variants and Protects Mice from SARS-CoV-2 Challenge.

A SARS-CoV-2 RBD vaccine fused to the chemokine MIP-3α elicits sustained murine antibody responses over 12 months and enhanced lung T-cell responses